Clarivate announces 2023 Journal Impact Factors

Clarivate^TM, owner of Web of Science, the citation index of scientific and scholarly publishing, has published its 2023 Journal Impact Factors^TM as part of its 2024 Journal Citation Reports^TM.

Bioscientifica is delighted to announce significant increases in Journal Impact Factors^TM for Reproduction and Fertility and EFORT Open Reviews. Reproduction and Fertility, an official journal of the Society for Reproduction and Fertility (SRF) has achieved a 2023 figure of 2.8. This represents a 33% increase on its first, and early-awarded 2022 Journal Impact Factor^TM of 2.1. It is a second quartile journal and is ranked number 16 of 39 in the ‘Reproductive Biology’ category in the latest Journal Citation Reports^TM.

EFORT Open Reviews, an official journal of the European Federation of National Associations of Orthopaedics and Traumatology (EFORT), has achieved a 2023 Journal Impact Factor^TM of 4.3. This represents a 26% increase on its 2022 figure. The journal has climbed to number 10 of 136 journals in the ‘Orthopedics’ category.

In other notable news, Reproduction, the sister hybrid title of Reproduction and Fertility and SRF’s flagship journal, has secured a first quartile position. It has achieved a 2023 Journal Impact Factor ^TM of 3.7, placing it at number 7 of 39 journals in the ‘Reproductive Biology’ category.

Bioscientifica is pleased to announce that the following titles have also achieved increases in Journal Impact Factors ^TM:

• Endocrine-Related Cancer now has a Journal Impact Factor^TM of over 4 after securing a 2023 figure of 4.1 and is in the second quartile.
• Journal of Molecular Endocrinology has achieved a 2023 Journal Impact Factor^TM of 3.6 and is in the second quartile.

John-Paul McDonald, Head of Editorial at Bioscientifica, said:

“We are pleased to announce the results of the latest Journal Citation Reports^TM. EFORT Open Reviews has significantly increased in citation impact, as has Reproduction and Fertility. The continued improvement in quality of our journals are thanks to the hard work, dedication, and valuable research of our authors and editors. On behalf of the Bioscientifica team I want to thank them as we look forward to where 2024’s research will take us.”

About Journal Impact Factors^TM

The Journal Impact Factor^TM is a citation metric often used as a proxy measure for a journal’s usefulness and quality, created by measuring the number of times an average paper is cited within a year. The 2023 Journal Impact Factors^TM are based on citations in 2023 to papers published in 2022 and 2021. Alongside this metric, Bioscientifica offers additional insights to help assess journal and article quality and impact. All journals provide article-level metrics, which provide traditional usage data, as well as Altmetric data.

Publishing with a purpose

Bioscientifica is owned by the Society for Endocrinology, a world-leading authority on hormones. We redistribute profits made through publishing back to the Society and its partner societies, helping advance scientific and clinical education and research in the field.

By publishing, reading and reviewing articles in Bioscientifica journals, you are directly supporting biomedical research and practice

Learn more about publishing with Bioscientifica.